Dr. Brandon Salke, PHARM.D, Pharmacist-in-charge, Optime Care
One of the biggest challenges for biopharmaceutical companies of rare and orphan disease patient populations is optimizing disease management in a way that enhances the patient journey and improves outcomes. As these companies seek innovative solution partners, a patient-first approach that offers specialty Rx pharmacist expertise is critical for securing insurance coverage, coordinating care, ensuring compliance, and, ultimately,
Read More
OurCrowd Launches $100M Pandemic Innovation Fund to Invest in Companies on Front Lines of COVID-19
What You Should Know:
- Israeli venture capital platform OurCrowd launches $100M Pandemic Fund to invest in companies on the front lines of COVID-19.
- The fund plans to raise $100M to invest in 15-20 companies focused on prevention & containment, treatment & healing, and community & disruption mitigation technology solutions to combat current and future pandemic.
OurCrowd,
a Jerusalem, Israel-based crowdfunded-venture investment platform, today
announced the launch
Read More
Corrona Acquires Patient Experience Company HealthiVibe
- Corrona acquires patient experience company HealthiVibe to further expand its presence in the patient experience marketplace. - HealthiVibe uses a systematic, evidence-based process to help pharmaceutical clients spearhead patient engagement initiatives at every stage of the product lifecycle.Corrona, LLC, a provider of real-world observational and syndicated registry data, announced today that it has acquired HealthiVibe, LLC, an Arlington, VA-based patient experience company. Financial
Read More
ConvergeHEALTH by Deloitte Launches New Digital Health Ecosystem Platforms
- ConvergeHEALTH MyPATH for Health and MyPATH for Connected Care help enhance the patient experience, improve adherence and generate a rich, longitudinal, real-world data set for insights.Today at HLTH 2019, ConvergeHEALTH by Deloitte announced the launch of a robust platform for the healthcare ecosystem that supports two critically important patient journeys. MyPATH for Health and MyPATH for Connected Care work together to connect and support patients and their care teams across the patient
Read More
MyHealthTeams Lands $9.44M to Expand Social Networks for Chronic Condition Communities
MyHealthTeams Co-founders Eric Peacock and Mary Ray
MyHealthTeams, a San Francisco, CA-based creator of the largest and fastest-growing social networks for people facing chronic health conditions raised $9.44 million in a Series B financing round led by strategic investor UCB, a global biopharmaceutical company. This financing brings total investment in MyHealthTeams to $26.84M, building on the company's Seed and Series A1, A2 and A3 rounds. Existing investors including Adams Street Partners,
Read More
IBM, KPMG, Merck and Walmart to Launch FDA Blockchain Pilot Program
IBM, KPMG, Merck, and Walmart today announced that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a blockchain pilot program in support of the U.S. Drug Supply Chain Security Act (DSCSA) that addresses requirements to identify, track and trace prescription medicines and vaccines distributed within the United States.Pilot Program OverviewThe FDA pilot program is intended to evaluate the use of blockchain technology to assist drug supply
Read More
Biofourmis Lands $35M for AI-Powered Digital Therapeutics Platform
Biofourmis, a Boston, MA-based digital therapeutics platform, today announced that it has raised $35 million in Series B funding led by Sequoia Capital/Sequoia India and co-led by Mass Mutual. The latest funding round will enable the company to advance its proprietary artificialintelligence (AI)-powered digital therapeutics platform and pipeline that treats and manages a range of complex chronic conditions.Digital Therapeutics is Redefining The Healthcare Value ChainFounded in 2015, Biofourmis
Read More
Clinical Operations Makes Highest Use of Artificial Intelligence, Tufts Study Finds
Clinical operations function makes the highest use of artificial intelligence (AI) (61%), followed by pharmacovigilance/safety/risk management (57%), and information technology (IT) (55%), according to an analysis recently completed by the Tufts Center for the Study of Drug Development. The analysis, summarized in the May/June Tufts CSDD Impact Report, reveals the pharmaceutical industry is adopting artificial intelligence (AI) on numerous fronts, from discovery and clinical development to risk
Read More
Pfizer & Concerto HealthAI Team Up on Precision Oncology Collaboration
Concerto HealthAI announced a deal
with Pfizer, through which Pfizer will
harness Concerto HealthAI’s eurekaHealth AI platform
and real-world data (RWD) to help identify new and more precise treatment
options as well as accelerate completion times for various outcomes studies. Concerto
HealthAI is comprised of the leading healthcare data scientists, health
economists, epidemiologists, and AI software engineers to advance flexible and
increasingly enterprise grade solutions for advancing RWE into
Read More
RDMD Lands $3M to Drive Patient-Accelerated Drug Development in Rare Diseases
San Francisco-based RDMD, a biopharma startup dedicated to accelerating research for patients with rare diseases, announced its $3 million seed financing backed by Lux Capital and Village Global, whose network of backers include Bill Gates, Mark Zuckerberg, Jeff Bezos, and Reid Hoffman. RDMD has developed a technology platform that generates deep data insights to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to get
Read More
